ALSO NOTED: Cell Therapeutics suspends enrollment; Morphotek wins orphan drug status; and much more...

> Cell Therapeutics announced on Friday that it was suspending enrollment in its clinical trial for Xyotax so it could study new data on recently enrolled patients. Following a meeting with the FDA. Cell Therapeutics is also amending the study to focus on the survival in women with normal estrogen levels. Release

> The FDA has granted orphan drug status to Morphotek's MORAb-009, a monoclonal antibody for pancreatic cancer. Release

> Amgen is reporting itself well satisfied with Phase II data on its cancer drug AMG-706. One analyst, though, called the results disappointing. Report

> U.S. investors have agreed to pay $524 million for Egypt's Amoun Pharmaceuticals, which manufactures and markets drugs under license. Report

> Targeted Genetics has restructured its debt to Biogen Idec. Report

> Novartis AG's anti-inflammatory drug Prexige has been cleared for EU approval. Report

> Melior Discovery in Exton, PA has inked a research pact with Merck. Release

And Finally… Despite a series of disappointments, researchers say they're exploring some promising new approaches to male contraception. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.